

# Richard F Pollock

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7120658/publications.pdf>

Version: 2024-02-01

52  
papers

669  
citations

686830

13  
h-index

642321

23  
g-index

52  
all docs

52  
docs citations

52  
times ranked

851  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus. <i>Journal of Medical Economics</i> , 2022, 25, 393-402.   | 1.0 | 7         |
| 2  | Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts. <i>Diabetes Therapy</i> , 2022, 13, 651-677.   | 1.2 | 0         |
| 3  | Economic Analysis of Intravenous Iron in Patients with Iron Deficiency Anemia Due to Inflammatory Bowel Disease: Considerations for Clinicians [Letter]. <i>ClinicoEconomics and Outcomes Research</i> , 2022, Volume 14, 163-165.                                      | 0.7 | 0         |
| 4  | Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose. <i>Journal of Medical Economics</i> , 2022, 25, 561-570.                            | 1.0 | 4         |
| 5  | A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 341-349.                            | 1.1 | 6         |
| 6  | Effects of Trial Population Selection on Quality of Life and Healthcare Decision-Making: A Systematic Review and Example in the Treatment of Hepatocellular Carcinoma with Radioembolization. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 835-841. | 0.7 | 0         |
| 7  | An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 9-18. | 0.7 | 9         |
| 8  | Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2575-2587.  | 1.2 | 19        |
| 9  | A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK. <i>Journal of Medical Economics</i> , 2020, 23, 1588-1597.               | 1.0 | 6         |
| 10 | Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis. <i>Advances in Therapy</i> , 2020, 37, 4446-4457.                     | 1.3 | 5         |
| 11 | Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 997-1009.           | 1.1 | 4         |
| 12 | A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. <i>Journal of Medical Economics</i> , 2020, 23, 751-759.   | 1.0 | 13        |
| 13 | Impact of Stigma on People Living with Chronic Hepatitis B. <i>Patient Related Outcome Measures</i> , 2020, Volume 11, 95-107.  | 0.7 | 46        |
| 14 | Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland. <i>Advances in Therapy</i> , 2020, 37, 1218-1232.  | 1.3 | 3         |
| 15 | A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. <i>Journal of Medical Economics</i> , 2020, 23, 593-602.                   | 1.0 | 10        |
| 16 | Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. <i>Expert Review of Hematology</i> , 2020, 13, 187-195.  | 1.0 | 34        |
| 17 | Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). <i>Applied Health Economics and Health Policy</i> , 2019, 17, 615-627.                                 | 1.0 | 10        |
| 18 | A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. <i>Expert Review of Hematology</i> , 2019, 12, 129-136.                            | 1.0 | 19        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. <i>Advances in Therapy</i> , 2019, 36, 1821-1825.   | 1.3 | 1         |
| 20 | A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. <i>Advances in Therapy</i> , 2019, 36, 1190-1199.  | 1.3 | 7         |
| 21 | Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1706-1714.  | 2.2 | 3         |
| 22 | Cost-Effectiveness Of The SQ&sup&gt; Gr&sup&gt; Grass SLIT-Tablet In Children With Allergic Rhinitis: A German Payer Perspective&lt;p&gt;. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 637-649.   | 0.7 | 2         |
| 23 | DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK. <i>Diabetes Therapy</i> , 2018, 9, 1217-1232.   | 1.2 | 11        |
| 24 | Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. <i>Value in Health</i> , 2018, 21, 724-731.   | 0.1 | 63        |
| 25 | Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. <i>Diabetes Therapy</i> , 2018, 9, 951-961.  | 1.2 | 16        |
| 26 | Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 357-366.   | 1.0 | 4         |
| 27 | Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. <i>Journal of Medical Economics</i> , 2018, 21, 144-151.   | 1.0 | 7         |
| 28 | Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden. <i>Diabetes Therapy</i> , 2018, 9, 87-99.   | 1.2 | 4         |
| 29 | An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. <i>Advances in Therapy</i> , 2018, 35, 2128-2137.   | 1.3 | 13        |
| 30 | Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 217-226. | 1.1 | 6         |
| 31 | An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 223-229.  | 0.7 | 2         |
| 32 | Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 1439-1446.  | 2.4 | 11        |
| 33 | Patient safety during procedural sedation using capnography monitoring: a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, e013402.   | 0.8 | 71        |
| 34 | The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus. <i>Value in Health</i> , 2017, 20, 985-991.   | 0.1 | 8         |
| 35 | A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. <i>Journal of Medical Economics</i> , 2017, 20, 213-220.  | 1.0 | 11        |
| 36 | A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 475-483.  | 0.7 | 13        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant. PLoS ONE, 2016, 11, e0160421.  | 1.1 | 63        |
| 38 | Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients. Advances in Therapy, 2016, 33, 345-356.  | 1.3 | 16        |
| 39 | Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice. Drugs - Real World Outcomes, 2016, 3, 61-68.                     | 0.7 | 6         |
| 40 | Cost-utility of abiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. Journal of Medical Economics, 2016, 19, 672-683.   | 1.0 | 9         |
| 41 | Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK. Journal of Medical Economics, 2015, 18, 1050-1059.                                  | 1.0 | 10        |
| 42 | An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices. Expert Opinion on Drug Delivery, 2015, 12, 353-360.   | 2.4 | 6         |
| 43 | Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK. Diabetes Research and Clinical Practice, 2015, 109, 95-103.                   | 1.1 | 5         |
| 44 | A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. Journal of Medical Economics, 2014, 17, 520-526. | 1.0 | 7         |
| 45 | Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. Journal of Medical Economics, 2013, 16, 1442-1452.   | 1.0 | 25        |
| 46 | Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK. Diabetes, Obesity and Metabolism, 2013, 15, 121-129.                                 | 2.2 | 25        |
| 47 | Laparoscopic adjustable gastric banding vs standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK. Journal of Medical Economics, 2013, 16, 249-259.  | 1.0 | 3         |
| 48 | Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis. Medical Devices: Evidence and Research, 2013, 6, 107.  | 0.4 | 1         |
| 49 | A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. Journal of Medical Economics, 2012, 15, 766-775.                              | 1.0 | 6         |
| 50 | A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin. Advances in Therapy, 2012, 29, 1051-1066.   | 1.3 | 4         |
| 51 | Long-Acting Insulin Analogs: A Review of Real-World Effectiveness in Patients with Type 2 Diabetes. Current Diabetes Reviews, 2011, 7, 61-74.  | 0.6 | 19        |
| 52 | The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective. Journal of Medical Economics, 2011, 14, 36-46.                             | 1.0 | 16        |